A subsidiary of Johnson & Johnson (NYSE: JNJ ) has filed a New Drug Application to the Food and Drug Administration for a combination treatment for type 2 diabetes, according to a company press release.
The treatment is a combination of an experimental medication, canagliflozin, and an established drug, metformin. Combined in a pill, the treatment is intended for patients with type 2 diabetes. This is a form of the disease in which either the body doesn't respond correctly to insulin or doesn't produce enough of the substance.
The new drug has been developed by Johnson & Johnson's Janssen Research and Development subsidiary.